Financing biotech companies in a post-COVID-19 era

It is undeniable that the COVID-19 crisis has impacted many industries throughout the world, not least the biotech sector.

Join Euronext’s second Biotech Leaders Conference to hear from our panel of experts on the pandemic’s impact on both private and public biotech financing as well as the M&A market. Euronext will also present the findings from our Biotech Barometer H1 2020 and biotech investors survey.

Watch the webinar brought to you by Euronext, KBC Securities, BioWin and Flanders.Bio by clicking the ‘START NOW’ button.

Our media partner for this webinar: Labiotech.eu


A panel of experts



Benoît van den Hove

Head of Listing at Euronext Brussels

Eric Castaldi

Eric Castaldi

Chief Financial Officer at argenx

Nicolas Meunier

Nicolas Meunier

Head of Advisory and IR Solutions at Euronext Corporate Services

Fabienne Van den Keere

Fabienne Van den Keere

Senior Advisor, Life Sciences at Korys

Cédric Moreau

Cédric Moreau

Partner at Sofinnova Partners

Bertrand Grimmonpré

Bertrand Grimmonpré

Chief Financial Officer at Miracor Medical

Nathalie Van den Haute

Nathalie Van den Haute

Executive Director Corporate Finance at KBC Securities

Topics covered in the webinar


What constitutes inside information under MAR (9)


Sign up now!



About Post-Listing Advisory

Euronext Post-Listing Advisory offers a full range of services and a dedicated team to advise and assist companies in leveraging their listing life:

Strategic 360° listing diagnostics

Equity story review

• IR action plan

Investor targeting

Market and listing analytics monitoring

• Board level reports

52118_EN-ECS-Post-Listing Advisory-update_GIF